New research suggests a link between some weight loss drugs and potentially blinding eye diseases. That risk is especially high for older adults. A recent study found that older adults with diabetes ...

All 50 states, D.C., and four U.S. territories signed off on the multi-billion dollar settlement proposal with OxyContin ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Wondering how to feel about Ozempic? These unexpected questions help reveal what may really be driving your reaction and how ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

LEXX Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that it had completed its GLP-1-H25-5 study last week and reported ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Doctors explain if Berberine, dubbed “Nature’s Ozempic,” can really help with menopause weight loss. Here’s what to know.